You are here
Jan E. Ehlert is cell biologist and has 10 years experience in basic research in innate immunology and 10 years in anti-cancer drug development in a biotech company. He is Head of the Division of Cellular Drug Discovery at ProQinase (KTB) and is specialized on cellular assay systems in oncology, cellular screening and 3D assay systems. He is co-inventor in three patents on compound classes issued to treat kinase-related cancer.
Role in SyStemAge:
Based on previuos experience in using endothelial and MSC co-culture spheroid systems for drug development, ProQinase (KTB) will develop novel 3D multi-cellular spheroid assay systems for B-CLL and MDS in close cooperation with groups in WP1 and WP3. ProQinase (KTB) will optimize these systems for medium-throughput analysis in order to screen compound libraries for substances that affect B-CLL cell viability while leaving non-malignant cells unharmed. Of special interest will be compounds that counteract resistance-mediating effects of the microenvironment on cytostatic treatment of B-CLL. In parallel, ProQinase (KTB) will establish cellular assay systems specific for targets involved in age-related B-CLL and MDS diseases based on the knowledge generated in WP4 in the course of the project.
SyStemAge partner from Jan 2013 - May 2015.
- Alajati A, et al. Nat Methods 5:439-45 (2008)
- Weber H, et al. Toxicol In Vitro 22:531-4 (2008)
- Tasler S, et al. Bioorg Med Chem 17:6728-37 (2009)